196 related articles for article (PubMed ID: 37483142)
1. Updates in chronic graft-versus-host disease management.
Malard F; Mohty M
Am J Hematol; 2023 Oct; 98(10):1637-1644. PubMed ID: 37483142
[TBL] [Abstract][Full Text] [Related]
2. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.
Zeiser R
J Clin Oncol; 2023 Apr; 41(10):1820-1824. PubMed ID: 36800551
[No Abstract] [Full Text] [Related]
3. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
Salhotra A; Sandhu K; O'Hearn J; Ali H; Nakamura R; Modi BG
Expert Rev Clin Immunol; 2023 Mar; 19(3):241-251. PubMed ID: 36440483
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
[TBL] [Abstract][Full Text] [Related]
5. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
[TBL] [Abstract][Full Text] [Related]
6. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
Cazeau N; Rodriguez S
Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
[TBL] [Abstract][Full Text] [Related]
7. Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM; Pidala J
Pharmacotherapy; 2020 Aug; 40(8):756-772. PubMed ID: 32441379
[TBL] [Abstract][Full Text] [Related]
8. Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.
Diep PP; Rueegg CS; Burman MM; Brinch L; Bø K; Fosså K; Landrø L; Loge JH; Lund MB; Massey RJ; Myrdal OH; Pathak M; Rimstad L; Tanem KE; Tjønnfjord GE; Aaløkken TM; Ruud E
J Adolesc Young Adult Oncol; 2023 Feb; 12(1):66-75. PubMed ID: 35544321
[No Abstract] [Full Text] [Related]
9. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
10. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
Hamad N; Bilmon I; Chee L; Henden A; Johnston A; Purtill D; Bajel A; Tey SK; Yeung D; Cole T; Lewis C; Butler J
Intern Med J; 2023 Dec; 53(12):2319-2329. PubMed ID: 38014511
[TBL] [Abstract][Full Text] [Related]
11. Psychological and physical function in allogeneic hematopoietic cell transplant survivors with chronic graft-versus-host disease.
Hansen JL; Juckett MB; Foster MA; Rumble ME; Morris KE; Hematti P; Costanzo ES
J Cancer Surviv; 2023 Jun; 17(3):646-656. PubMed ID: 36917433
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
13. Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
Baumrin E; Loren AW; Falk SJ; Mays JW; Cowen EW
J Am Acad Dermatol; 2024 Jan; 90(1):19-36. PubMed ID: 36572064
[TBL] [Abstract][Full Text] [Related]
14. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
15. Low-dose rituximab in steroid-refractory chronic graft-versus-host disease.
Colunga-Pedraza PR; Barbosa-Castillo LM; Coronado-Alejandro EU; Vaquera-Alfaro HA; López-Reyna IG; Colunga-Pedraza JE; Gómez-Almaguer D
Transpl Immunol; 2023 Dec; 81():101959. PubMed ID: 37972876
[TBL] [Abstract][Full Text] [Related]
16. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
[TBL] [Abstract][Full Text] [Related]
17. Recent advances and research progress in biomarkers for chronic graft versus host disease.
Ji R; Li Y; Huang R; Xiong J; Wang X; Zhang X
Crit Rev Oncol Hematol; 2023 Jun; 186():103993. PubMed ID: 37061073
[TBL] [Abstract][Full Text] [Related]
18. Three US Food and Drug Administration-approved therapies for chronic GVHD.
Zeiser R; Lee SJ
Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
Gagliardi TA; Milner J; Cairo MS; Steinberg A
Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
[TBL] [Abstract][Full Text] [Related]
20. Critical digital ischemia and biliary cholangitis related to graft versus host disease: A case report and systematic literature review.
Hidalgo Calleja C; Montilla Morales CA; Sánchez González MD; Pastor Navarro S; Ibáñez Martínez M; Conde Ferreiros A; López Corral L
Medicine (Baltimore); 2023 Jan; 102(2):e32495. PubMed ID: 36637943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]